Abstract.

Pacemaker implantation is becoming increasingly common in patients with breast cancer. Comprehensive treatment options, such as surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy, have greatly improved the prognosis of patients with breast cancer. In particular, radiotherapy is an important means of comprehensive breast cancer treatment that can reduce recurrence and prolong survival in high-risk patients who underwent mastectomy. The pacemaker electrical pulse generator is typically implanted subcutaneously in the left subclavian area above the pectoral muscle through the subclavian vein. The present report implemented a new method of 'temporary pacemaker electrode and permanent artificial pacemaker placement' through the right axillary vein in a patient with breast cancer. An electrical pulse generator was placed in the right subcutaneous subclavian tissue. The pacemaker was placed under the right clavicle, and the pacemaker was included as organ at risk (OAR). Dose of planning organ at risk volume (PRV) with additional 6 mm margin to the pacemaker was limited during radiotherapy planning design. This patient with breast cancer, who was also complicated with other underlying comorbidities (such as atrial fibrillation, coronary atherosclerosis, cardiac insufficiency, hypertension, type 2 diabetes mellitus) and implanted with a cardiac pacemaker, was treated with safe (means that the patient has not developed heart disease because of the pacemaker problem) and effective (tumor can be effectively controlled under the condition that the pacemaker does not malfunction) radiotherapy. At present, the patient has successfully completed radiation therapy for breast cancer with no recurrence or metastasis. To the best of our knowledge, the present report is the first to document this application, demonstrating the treatment of a patient with breast cancer and cardiac pacemaker implantation, which is worthy of further study and continuous improvement in clinical practice.

Introduction

Breast cancer is a major type of cancer that threaten the health of women worldwide and has been attracting the attention of researchers worldwide. Among the 185 countries/regions in the world, 159 countries have the highest incidence of breast cancer, with the highest incidence and death rate of female cancer, with the incidence and death rate of 47.8 and 13.6% per 100,000 people, respectively (1). After standardized treatment of early breast cancer, the 5-year survival rate of breast cancer patients can reach 95% (2). The incidence and mortality of cancer are increasing rapidly worldwide, which is related to the aging of population and the increase of population. With the improvement of people's life quality and the improvement of pacing engineering, the indications for pacemaker implantation are gradually expanding. At present, the clinical application of pacemaker therapy, especially ordinary pacemaker, has become very popular. According to the 2012 ACCF/AHA/HRS Guidelines for Implanted Devices, common pacemaker implantation indications include 11 aspects (3) (1) Appropriate indications for permanent pacemaker implantation in patients with abnormal sinus node function; (2) Indications for permanent pacemaker implantation in adults with acquired atrioventricular block; (3) Indications for permanent pacemaker implantation in patients with chronic double branch block; (4) Indications for permanent pacemaker implantation in patients with abnormal sinus node function; (2) Indications for permanent pacemaker implantation in adults with acquired atrioventricular block; (3) Indications for permanent pacemaker implantation in patients with chronic double branch block; (4) Indications for permanent pacemaker implantation in patients with chronic double branch block; (5) Indications for permanent pacemaker implantation in patients with hypertrophic cardiomyopathy; (6) Indications for permanent pacemaker implantation in patients with congenital heart disease (CHD). How to improve the...
survival rate and quality of life of breast cancer patients with pacemakers is an issue that we need to pay common attention to. At present, the treatment of breast cancer has entered the era of comprehensive therapy, including surgery, radiation therapy, chemotherapy, targeted therapy, endocrine therapy and immunotherapy. Therefore, when radiotherapy is performed on such patients, the path of pacemaker implantation should be considered for those who need pacemaker implantation, so as to prepare for safe radiotherapy with pacemaker irradiation dose control in the later stage. Ionizing radiation generated during radiotherapy can cause charge accumulation and abnormal current in the semiconductor components of cardiac pacemaker, which can cause pacemaker failure or interfere with the function of pacemaker, and even induce malignant arrhythmia. After implantation of the pacemaker electrode in the heart cavity, a foreign body rejection inflammatory reaction occurred at the electrode joint/tissue interface, resulting in inflammatory edema. Cardiomyocyte damage and inflammatory edema caused by radiotherapy can inhibit the conduction of electrical pulse signal of the pacemaker, and even cause working obstacles for the pacemaker in severe cases. Therefore, Medtronic recommends that the radiation dose of the pacemaker should not be greater than or equal to 5 Gy, and that the pacemaker and pulse generator should be placed in the irradiation field. When radiotherapists use 3D radiotherapy to delineate the target area, they should define the pacemaker as the organ at risk (OAR) and ensure that its maximum tolerance is 2 Gy. Tumor patients with pacemaker implantation can safely and effectively complete radiotherapy under certain treatment conditions, which requires us to take full consideration of the specific situation of patients in the process of making radiotherapy plan and implementing radiotherapy, so as to minimize the influence of various factors on pacemaker.

Case report

In May 2020, the patient, a 64-year-old female, found a left axillary mass that was not causing any redness, swelling or pain. In addition, the left axillary mass did not shrink significantly after oral traditional Chinese medicine (TCM) (100 ml twice a day, orally in the morning and evening). This manifestation was not followed by further examination or treatment. The patient's left axillary mass not only increased in size by December 2020, but also aggravated, meaning that the chemotherapy regimen had to be adjusted to that of the THP regimen (docetaxel 100 mg d1, carboplatin 500 mg d1, trastuzumab 400 mg d1 and pertuzumab 840 mg d1) was given for two cycles (3 weeks each). After chemotherapy, the patient's renal function was aggravated, meaning that the chemotherapy regimen had to be adjusted to that of the THP regimen (docetaxel 100 mg d1, trastuzumab 400 mg d1 and pertuzumab 840 mg d1) for four cycles (3 weeks each). Chemotherapy was followed by endocrine therapy with trozole, followed by targeted therapy. As the patient exhibited complications of atrial fibrillation, coronary atherosclerosis, cardiac insufficiency, hypertension and type 2 diabetes mellitus, antitumor therapy was suspended. The patient was subsequently admitted into the Department of Cardiology of West China Hospital of Sichuan University (Chengdu, China) in December 2020. The results of the medical examination are summarized in Table I.

The patient was ultimately diagnosed with the following: i) Atrial fibrillation with intermittent third-degree atrioventricular block; ii) cardiac insufficiency with grade III cardiac function (General physical activity is significantly limited. No symptoms at rest, less than normal physical activity can cause fatigue, palpitations, asthma or angina); iii) hypertrophic cardiomyopathy; iv) coronary atherosclerosis; v) hypertension; vi) type 2 diabetes mellitus; vii) left breast cancer with axillary lymph node metastasis; and viii) chronic renal insufficiency.

Considering that the patient was diagnosed with left breast cancer with axillary lymph node metastasis and required postoperative radiotherapy, a temporary pacing electrode and permanent artificial cardiac pacemaker placement’ (model no. A3DR01; Medtronic, Inc.) procedure was performed using the right axillary vein approach. The electrical pulse generator (model no. A3DR01; Medtronic, Inc.) was placed in the right subclavian subcutaneous tissue.

In January 2021, the patient underwent left radical mastectomy and left axillary lymph node dissection. Postoperative pathological (HE staining and immunohistochemical staining of metastatic lymph nodes of breast cancer) assessment showed the following: i) Invasive ductal carcinoma of the left breast (grade III; tumor size, 2.0x1.8x1.5 cm); ii) lymphovascular invasion; and iii) positivity for estrogen receptor (strong–moderate; ~30% positive cells), progesterone receptor (moderate–strong; ~70%), human epidermal growth factor receptor 2 (HER2; predisposition to 3+), HER2–fluorescence in situ hybridization and Ki 67 (~30%; data not shown). The ‘left subclavian lymph node’ (1/8.8 were tested, and one was positive) and ‘left axillary level 1 and 2 lymph node’ (13/28,28 axillary lymph node were examined, and cancer metastasis was found in 13 of them) were subsequently examined for cancer metastasis. This was followed by the postoperative diagnosis of invasive ductal carcinoma of the left breast (pT1N3M0 stage III; HER2 overexpression type). After surgery, the TCbHP chemotherapy regimen (docetaxel 108 mg d1, carboplatin 500 mg d1, trastuzumab 400 mg d1 and pertuzumab 840 mg d1) was given for two cycles (3 weeks each). After chemotherapy, the patient's renal function was aggravated, meaning that the chemotherapy regimen had to be adjusted to that of the THP regimen (docetaxel 100 mg d1, trastuzumab 400 mg d1 and pertuzumab 840 mg d1) for four cycles (3 weeks each). Chemotherapy was followed by endocrine therapy with Letrozole endocrine therapy (2.5 mg/day for 5 years), thereby targeted therapy was continued. The patient also attended the department of Radiotherapy, West China Hospital to receive radiotherapy. The radiotherapy physician fully communicated with the patient and family members about the procedures of postoperative radiotherapy, in addition to possible side effects and impact on the pacemaker (pacemaker dysfunction and permanent damage), before the patient signed the radiotherapy informed consent form.
Laboratory examination  
Serum creatinine, 151 µmol/l; estimated glomerular filtration rate, 31.46 ml/min/1.73 m²

Enhanced MRI of cardiac function  
Asymmetrical thickening of the left ventricular wall. The thickest point was 2.3 cm and myocardial perfusion defect was observed with extensive delayed enhancement, slightly decreased left ventricular ejection fraction (45.8%), significantly decreased right ventricular ejection fraction (31.2%) and enlarged left and right atria

Echocardiogram  
The left ventricle was enlarged, the interventricular septum was significantly thickened, the posterior wall of the left ventricle was slightly thicker and the ascending aorta was widened. Tricuspid regurgitation (mild) and normal left ventricular systolic diastolic function were observed

Dynamic electrocardiogram  
Slow ventricular rate atrial fibrillation, minimum heart rate 29 beats/min, transient third-degree atrioventricular block, ventricular escape heart rate, complete right ventricular block and ST-T changes seen during sleep

Table I. Hospital examination results of the patient.

| Test                              | Result                                                                 |
|-----------------------------------|------------------------------------------------------------------------|
| Dynamic electrocardiogram         | Slow ventricular rate atrial fibrillation, minimum heart rate 29 beats/min, transient third-degree atrioventricular block, ventricular escape heart rate, complete right ventricular block and ST-T changes seen during sleep |
| Echocardiogram                    | The left ventricle was enlarged, the interventricular septum was significantly thickened, the posterior wall of the left ventricle was slightly thicker and the ascending aorta was widened. Tricuspid regurgitation (mild) and normal left ventricular systolic diastolic function were observed |
| Enhanced MRI of cardiac function  | Asymmetrical thickening of the left ventricular wall. The thickest point was 2.3 cm and myocardial perfusion defect was observed with extensive delayed enhancement, slightly decreased left ventricular ejection fraction (45.8%), significantly decreased right ventricular ejection fraction (31.2%) and enlarged left and right atria |
| Laboratory examination            | Serum creatinine, 151 µmol/l; estimated glomerular filtration rate, 31.46 ml/min/1.73 m² |
also instructed to immediately raise her hand to report symptoms, including palpitation or chest tightness, in which case the therapist would immediately stop radiotherapy. The treatment room was equipped with first-aid equipment.
Furthermore, if the patient encountered an emergency (such as Palpitation, chest tightness, tight breath), the radiotherapy physician, cardiologist and emergency physician would be immediately contacted for on-site first aid. The patient successfully completed radiotherapy. During radiotherapy, when the patient's cardiac pacemaker was adjusted to the asynchronous pacing mode, light activities (General physical activity, such as climbing the stairs 2 floors) were causing tiredness and palpitations. After adjusting back to the original mode, the symptoms were relieved and there was no cough, tightness of breath or second-degree skin reaction in the irradiated area.

As of April 2022, the patient has completed radiotherapy for 5 months and has not complained of any discomfort. There was no recurrence or metastasis of the tumor in a comprehensive review. Specific examinations included color ultrasound of breast chest wall, upper and lower clavicle, axillary lymph nodes, abdomen, and chest enhanced CT. The cardiac pacemaker remains in normal working condition.

Discussion

According to the Global Cancer Observatory database, there were 2,261,419 new cases of breast cancer in 2021, accounting for 11.7% of the total incidence of cancer (5). In particular, breast cancer has for the first time surpassed lung cancer as the most common cancer in women worldwide (5). At present, the number of patients with cardiovascular diseases in China has increased to >330 million, where there are ~1 million patients with bradycardia, with an average annual increase of 300,000-400,000 (6,7). For patients with bradycardia, implantation of a cardiac pacemaker is the only effective treatment (6). With the increase in cases of cardiac pacemaker implantations in China, the number of patients with heart disease complicated with tumors is likely to correspondingly increase. The safe implementation of radiotherapy regimens for such patients is an important obstacle faced by tumor radiotherapy physicians and therapists.

Cardiac implantable electronic devices (CIEDs) include cardiac pacemakers and implantable cardiac defibrillators (ICDs) (8). There are various factors that affect the use of CIEDs during radiotherapy. Ionizing radiation and electromagnetic fields generated during radiotherapy may cause pacemaker dysfunction, interfere with pacing function or even induce arrhythmias (9). Device malfunction is reported in 2.5% of patients with pacemakers and 6.8% of patients with ICD after radiotherapy (10). Regarding the influence of radiation dose and energy on CIED, the American Association of Physicists in Medicine (AAPM) recommended in its report no. 34 published in 1994 that in such patients, a cumulative dose received by pacemaker <2 Gy should be considered when planning radiotherapy (9). In addition, Memorial Sloan Kettering Cancer Center suggested that CIEDs should be outlined as organs at risk and optimized to the lowest dose, with a limit of 2-5 Gy for pacemakers and 0.5-2 Gy for ICDs (11). The device may suffer significant damage from direct exposure or from the use of energy >6 MV (10,12). Using energy of ≥10 MV, secondary neutrons can damage random access memory and additional semiconductors in modern devices (9,13). Finally, the distance between the radiation field and the pacemaker will affect the pacemaker, and the pacemaker will be placed in the irradiation field, which will cause the pacemaker device working obstacles. Irradiation field recommendations do not consider pacemakers (8). The pacemaker electrical pulse generator is normally implanted subcutaneously in the left subclavian area above the pectoral muscle through the subclavian vein. However, due to the left breast cancer radical surgery, in the present case the cardiologist chose the right axillary vein approach to implant the pulse generator subcutaneous device in the right clavicle area in preparation for the subsequent

| Pacemaker position | Cone beam computerized tomography, cGy | Volumetric modulated arc therapy, cGy |
|--------------------|----------------------------------------|-------------------------------------|
| Inner              | 7.06                                   | 9.80                                |
| Central            | 3.58                                   | 9.39                                |
| Outer              | 3.90                                   | 6.18                                |
radiotherapy. In addition, in the present case the manufacturer's protocols accompanying the pacemaker implanted into the patient indicated that to prevent excessive perception, the pacemaker can be programmed to asynchronous pacing mode, where such pacemaker parameters can be restored after radiotherapy. To prevent device damage, the pacemaker should be exposed to a dose of <5 Gy based on manufacturer's guidelines.

Indications for radiotherapy after mastectomy for patients with breast cancer include T3-4 and T1-2 tumors, ≥4 axillary metastatic lymph nodes and 1-3 positive axillary lymph node metastases (14). Therefore, there is a larger degree of heterogeneity in factors determining the indications for radiotherapy, not only with regards to the clinical and pathological characteristics of the patient, but also considering the systemic treatment (15). A previous meta-analysis performed by the Early Breast Cancer Clinical Trials Collaborative Group showed that for patients with positive axillary lymph nodes, post-operative radiotherapy reduced the 10-year overall recurrence rate and 20-year breast cancer-related mortality rate by 8.8 and 9.3%, respectively, in patients with ≥4 positive axillary lymph nodes (15). The target areas of radiotherapy mainly include the chest wall and supraclavicular lymphatic drainage area. By contrast, the efficacy of internal breast irradiation is controversial and is recommended in patients at high risk, such as patients with axillary metastatic lymph nodes ≥4. Modern precision radiotherapy techniques such as stereotactic radiotherapy, three-dimensional conformal radiotherapy and intensity modulated radiotherapy are recommended to accurately assess the dose of radiation delivered to normal tissues such as the heart. In addition, these techniques are recommended to adequately balance the benefits and risks of systemic therapy and radiotherapy in terms of heart-related injury following internal breast prophylaxis irradiation (15).

Although comprehensive treatment strategies of breast cancer has improved the long-term survival rate of patients, radiotherapy-induced late cardiotoxicity has emerged as a subject of concern (16). Darby et al (17) previously reported that ischemic heart disease after radiotherapy for breast cancer generally occurs 5 years after radiotherapy. In addition, the incidence is associated with the mean cardiac radiotherapy dose, such that for each increment in the mean dose by 1 Gy, the incidence of cardiac events, such as myocardial infarction, increases by 7.4%, with no significant threshold which means there was no significant minimum or maximum dose increase associated with the incidence of cardiac events (17). The most well-documented cardiotoxicity reduction study was performed in relation to the DIBH (Deep Inspiration Breath Holding) technique (18), which is typically used in combination with 3D conformal radiotherapy planning in tangential fields. Modern radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT) and volumetric IMRT, have shown limited and inconsistent results in reducing cardiac dose. However, the results

### Table III. Patient risk category.

| Patient classification | <2 Gy | 2-10 Gy | >10 Gy |
|------------------------|-------|--------|--------|
| Pacing-independent<sup>a</sup> | Low risk | Intermediate risk | High risk |
| Pacing-dependent<sup>b</sup> | Intermediate risk | High risk | High risk |

<sup>a</sup>Intrinsic ventricular rhythm of the heart is >30 beats/min and no emergencies related to bradycardia occur. <sup>b</sup>Abnormal operation of the implanted device causes a sudden stop of the heart rhythm, whilst the intrinsic rhythm of the heart is >30 beats/min, creating an emergency. Adapted from German Society of Radiation Oncology guideline, 2015 (12).
A previous dosimetry study by Popescu et al (20) found that conventional intensity-modulated radiotherapy (IMRT) and VMAT improved the dose distribution in the target region compared with that following 3D conformal radiotherapy with tangent field. Compared with conventional IMRT, VMAT reduces the average dose delivered to the heart and lung, resulting in improved protection of the organs at risk and shorter irradiation time (21). However, both techniques do increase the low-dose irradiation of surrounding healthy tissues at the same time. VMAT is also the treatment that it is commonly adopted by the authors of the present case report (20).

According to Guidelines for Chinese Physicians (15) and postoperative staging of the patient, the target area of radiotherapy should include the left chest wall and the lymphatic drainage area above and below the left clavicle. Subject to cardiac dose safety, the internal breast lymphatic drainage area can also be considered. The patient in the present case exhibited a combination of hypertrophic cardiomyopathy, an enlarged heart adjacent to the left chest wall and pacemaker implantation. Chemotherapy containing paclitaxel and targeted anti-HER2 therapy are cardiotoxic, meaning that radiotherapy requires strict control in terms of both cardiac and pacemaker doses.

Table IV. Dose region and risk category.

| Patient classification | <2 Gy | 2-5 Gy | >5 Gy | Neutrons present |
|------------------------|------|-------|------|------------------|
| Pacing independent     | Low risk | Medium risk | High risk | High risk |
| Pacing dependent       | Medium risk | Medium risk | High risk | High risk |

Adapted from Association of Physicists in Medicine TG-203 report, 2019 (21).

Figure 5. Alignment results of the optical surface imaging system. The main regions of interest are chest wall, upper and lower clavicle, vertebral body, and heart. Lat, lateral; long, longitudinal; vert, vertical; rot, Z axis rotation Angle; Roll, Y-axis rotation Angle; Pitch means X axis rotation Angle.
which poses a great challenge to radiotherapists and physicians (22). We first adopted the DIBH-ABC technology, which is the characteristic technology of our hospital, and adopted the active breathing control device ABC to achieve deep inspiratory breath holding. ABC is a respiratory gating device manufactured by Swedish Medical company. Breathing training was performed for the patient for a week but discontinued because the patient's breath hold time was too short to cooperate with the technique. To improve the conformability of the target area and lower the cardiac dose, the radiation physicist used both static IMRT and VMAT techniques. Finally, the VMAT radiotherapy plan for the four arcs of the target area segment reached the limiting dose for organ and pacemaker endangerment, after discarding the internal breast target area and reducing the prescribed dose of radiotherapy to 46 Gy/23f. The upper part of the two non-tangential field direction arcs with smaller irradiation angles reduced the dose delivered to the pacemaker. The lower part of the two tangential field direction arcs with high conformity of the target area provided an improved control over the dose delivered to the heart and lung, which locked the lead gate adjacent to the pacemaker. This reduced the leakage of radiation from the multi-Leaf Collimator, further controlling the pacemaker dose. Due to the use of complex VMAT plans in the target area, the accuracy of the dose was verified by the radiation physicist before treatment. Chan et al (11) recommended the use of in vitro dose detection systems, such as optically-stimulated luminescence dosimeters, thermoluminescent dosimeters and diodes. The dose delivered to the device is measured on the first day of treatment to predict the cumulative dose throughout radiotherapy (11). The dose delivered to the pacemaker was measured on the first treatment, where the estimated maximum cumulative dose of the pacemaker throughout radiotherapy was 225.4 cGy, which was consistent with the radiotherapy plan. The maximum irradiated dose delivered to the device at a cumulative dose of the pacemaker throughout radiotherapy (11). The patient received radiotherapy under the medical ELekta Synerg accelerator. When CBCT was performed, the initial angle of the scan sequence was pre-set at 120-260°. The collimator used S20 (collimator with a small-field axial field length of 276.7 mm) and the F1 filter plate to reduce the radiation dose delivered to the pacemaker. F1 is a conformal filter, the collimator and filter are placed in the two slots of the KV source arm. In this manner, the quality of treatment and the safety of radiotherapy were optimized.

Various guidelines and reviews have been published internationally to guide the management of patients with implanted cardiac electronic devices receiving radiotherapy (11,12,29,30). Patients are first classified into low-, intermediate- and high-risk groups by cumulative dose and pacing dependence (Table III), with slight differences among different guidelines. For example, the risk stratification reported in the 2019 AAPM TG-203 guidelines (30) (Table IV) incorporated the presence or absence of neutron irradiation in addition to proposing stricter limits on the cumulative dose. Patients are then managed according to the different stages of radiotherapy with different risk stratifications. Although the recommendations for patient management vary slightly among guidelines, all emphasize the importance of close multidisciplinary collaboration among cardiologists, radiation oncologists, physicists, therapists and pacemaker specialist technicians. General management measures during radiotherapy include reprogramming to asynchronous pacing or placing magnets for pacemaker-dependent patients, delaying antiarrhythmic therapy and reprogramming or placing magnets at each radiotherapy session for patients with ICD (29). Different management measures are used for patients in different risk strata. For low-risk patients, the patient symptoms and vital signs are closely monitored, whilst weekly device checks are required for those with ICDs only (29). For medium-risk patients, emergency equipment is required (such as cardiac monitor and defibrillator), whilst for device-dependent patients, an external pacemaker should be available and a team of professionals (cardiologist, pacemaker specialist technician and resuscitator) should be available to ensure immediate intervention in case of an emergency, in addition to the device being checked weekly. For high-risk patients, the benefits of treatment should be weighed against the risk of inducing damage if device repositioning is not feasible. Electrocardiogram (ECG) monitoring should be...
performed at each radiotherapy session and the device should be checked within 24 h after each treatment (29). The device should be regulated at 1, 3 and 6 months after the end of radiotherapy (29). In the present case report, the patient had a minimum cardiac rhythm of 29 beats/min on the 24-h ambulatory ECG before pacemaker implantation and the predicted maximum pacemaker involvement dose was 296.0 cGy. According to the AAPM TG-203 report, since the patient was classified to be a medium-risk patient, the aforementioned recommended management measures were followed. The patient successfully completed radiotherapy with only discomfort caused by changes in pacing patterns, with no pacemaker damage or functional abnormalities found upon regular cardiology examinations after radiotherapy was completed.

In conclusion, in the era of precision radiotherapy, the use of modern radiotherapy techniques, including radiotherapy planning assessment systems, intensity-modulated radiotherapy techniques, extracorporeal dosimetry and real-time image guidance, allows for the accurate assessment, limitation and prediction of the pacemaker dose. In addition, the use of risk-stratified management measures, with the participation of a multidisciplinary team, allows for the safe administration of radiotherapy to patients with pacemaker-implanted tumors.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

YW and LX drafted the manuscript. LX performed the manuscript review and revision. JZ, YH, CL and YS performed patient planning, radiotherapy and data collection. LZ performed dose verification and pacemaker dosimetry. YW performed data analysis and drafted the manuscript. LX interpreted the data. YW and LX confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Written informed consent was obtained from the patient for publication of the present case report.

Competing interests

The authors declare that they have no competing interests.

References

1. Cao M and Chen W: Interpretation of Global cancer statistics in GLOBOCAN 2020. Chin J Frontier Medicine (electronic edition) 13: 63–69, 2021 (In Chinese).
2. Coldman AJ and Phillips N: Breast cancer survival and prognosis by screening history. Br J Cancer 110: 556–559, 2014.
3. Hua W and Zhang S: Interpretation of the 2012 ACCF/AHA/HRS Guidelines for the treatment of arrhythmia devices. Chin J Cardiac Arrhythmias 2012: 467, 2012 (In Chinese).
4. Bradley JA and Mendenhall NP: Novel Radiotherapy Techniques for Breast Cancer. Am Rev Med 69: 277–288, 2018.
5. Duggan C, Trapani D, Ilbawi AM, Fidarova E, Luverasanne M, Curigliano G, Bray F and Anderson BO: National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: A population-based analysis. Lancet Oncol 22: 1632–1642, 2021.
6. National Center for Cardiovascular Diseases: Annual report on cardiovascular health and diseases in China 2020. J Cardiovasc Pulm Dis 40: 1005–1009, 2021.
7. National Cardiovascular Disease Center: China Cardiovascular Health and Disease Report 2019. Science Press, 2020.
8. Zhang T and Li X: Research progress of radiotherapy for patients with tumor with implanted cardiac pacemaker. Chin J Interventional Cardiol 37: 237-240, 2017 (In Chinese).
9. Marbach J, Sontag MR, Van Dyk J and Wolbarst AB: Management of radiation oncology patients with implanted cardiac pacemakers: Report of AAPM Task Group No. 34. American Association of Physicists in Medicine. Med Phys 21: 85–90, 1994.
10. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Johansen MB, Madsen LB and Riabhi S: Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: A population-based cohort study. Pacing Clin Electrophysiol 38: 343–356, 2015.
11. Chan MF, Young C, Gelblum D, Shi C, Roncon C, Hipp E, Li J and Wang D: A Review and Analysis of Managing Commonly Seen Implanted Devices for Patients Undergoing Radiation Therapy. Adv Radiat Oncol 6: 100732, 2021.
12. Gauter-Fleckenstein B, Israel CW, Dorenkamp M, Dunst J, Roser M, Schimpf R, Steil V, Schäfer J, Höller U and Wenz F; DEGRO/DGK: DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices. Strahlenther Onkol 195: 861–871, 2019.
13. Soejima T, Yoden E, Nishimura Y, Ono S, Yoshida A, Fukuda H, Fukuhara N, Sasaki R, Tsujino K and Norihisa Y: Radiation therapy in patients with implanted cardiac pacemakers and implantable cardioverter defibrillators: A prospective study in Japan. J Radiat Res 52: 516–521, 2011.
14. Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J and Han W: Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol 18: 792–804, 2021.
15. Chinese Physicians Association, Radiation Oncology Therapy Physicians Branch: Radiation Therapy Guidelines for Breast Cancer (CMA 2020 Edition). Chin J Radiat Oncol 30: 321–342, 2021 (In Chinese).
16. Wanga S: Radiotherapy for Left-sided Breast Cancer: Focusing on Heart Dosimetry (unpublished PhD thesis). Zhejiang University, 2018.
17. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Curigliano G, Dowsett M, Forbes I, Fallowfield L, Fentiman I, Gago-Dominguez M, Goldhirsch A, Gnant M, Gusterson B, Hall E, Haddad M, Halmos B, Hudis C, Imai Y, Jatoi A, Langer AK, Lenz H, Maisonneuve P, McPherson J, Paik S, Paterson J, Peto J, Pirker R, Pujol JL, Robson M, Solin L, Taylor C, Trastek V, Veronesi U, Verma S, Voss M, Walewski JN, Wild C, Wood WC, Yancik R and de Bono J: International breast cancer dicsovery centre (IBDC). Strahlentherapi Onkol 191: 393–404, 2015.
18. Duma MN, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Hehr T, Krug D, Haase W, Harms W, Johansen MB, Madsen LB and Riabhi S: Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: A population-based cohort study. Pacing Clin Electrophysiol 38: 343–356, 2015.
19. Chan MF, Young C, Gelblum D, Shi C, Roncon C, Hipp E, Li J and Wang D: A Review and Analysis of Managing Commonly Seen Implanted Devices for Patients Undergoing Radiation Therapy. Adv Radiat Oncol 6: 100732, 2021.
20. Gauter-Fleckenstein B, Israel CW, Dorenkamp M, Dunst J, Roser M, Schimpf R, Steil V, Schäfer J, Höller U and Wenz F; DEGRO/DGK: DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices. Strahlenther Onkol 195: 861–871, 2019.
21. Ahmad SS, Duke S, Jena R, Williams MV and Burnet NG: Advances in radiotherapy. BMJ 345: e7765, 2012.
22. Han Y, Chen K, Li Q and Chen J: Study on the application of A-DIBH method to reduce the cardiac dose in patients undergoing radiotherapy after breast-conserving surgery for left-sided breast cancer. Chin Modern Doctor 60: 84-87+197, 2022 (In Chinese).
23. Borst GR, Sonke JJ, Betgen A, Remeijer P, van Herk M and Lebesque JV: Kilo-voltage cone-beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device. Int J Radiat Oncol Biol Phys 68: 555-561, 2007.
24. Hansen EK, Larson DA, Aubin M, Chen J, Descovich M, Gillis AM, Morin O, Xia P and Pouliot J: Image-guided radiotherapy using megavoltage cone-beam computed tomography for treatment of paraspinal tumors in the presence of orthopedic hardware. Int J Radiat Oncol Biol Phys 66: 323-326, 2006.
25. Wu Y, Zhong R, Liu Z, Ye C, Chen L, He Z and Bai S: Management of cone beam CT technique for patient positioning in radiotherapy. J Cancer Control Treatment 23: 156-158, 2010 (In Chinese).
26. Chen L, Bai L, Li G, Quan H and Bai S: Real-time motion tracking accuracy of optical surface imaging system. Chin J Med Physics 38: 1053-1056, 2021 (In Chinese).
27. Wikström K, Nilsson K, Isacsson U and Ahnesjö A: A comparison of patient position displacements from body surface laser scanning and cone beam CT bone registrations for radiotherapy of pelvic targets. Acta Oncol 53: 268-277, 2014.
28. Gierga DP, Riboldi M, Turcotte JC, Sharp GC, Jiang SB, Taghian AG and Chen GT: Comparison of target registration errors for multiple image-guided techniques in accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 70: 1239-1246, 2008.
29. Salerno F, Gomellini S, Caruso C, Barbara R, Musio D, Coppi T, Cardinale M, Tombolini V and de Paula U: Management of radiation therapy patients with cardiac defibrillator or pacemaker. Radiol Med 121: 515-520, 2016.
30. Miften M, Mihailidis D, Kry SF, Reft C, Esquivel C, Farr J, Followill D, Hurkmans C, Liu A, Gayou O, et al: Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: A Report of the AAPM TG-203†. Med Phys 46: e757-e788, 2019.